Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


Articles published in Int J Urol

Retrieve available abstracts of 115 articles:
HTML format



Single Articles


    September 2022
  1. LEOW JJ, Chen K, Yuen JSP
    Editorial Comment to Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle invasive bladder cancer.
    Int J Urol. 2022 Sep 12. doi: 10.1111/iju.15037.
    PubMed    


    July 2022
  2. IDE H
    Editorial Comment from Dr Ide to Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.14988.
    PubMed    


  3. NASELLI A, Pirola GM
    Editorial Comment from Dr Naselli and Dr Pirola to Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.15000.
    PubMed    


  4. TOCHIGI K, Nagayama J, Bando S, Ishiyama A, et al
    Relationship between the number of lymph nodes dissected and prognosis in muscle-invasive bladder cancer in the era of neoadjuvant chemotherapy.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.14974.
    PubMed     Abstract available


  5. MURAKAMI Y, Matsumoto K, Miyake M, Amano N, et al
    Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.14976.
    PubMed     Abstract available


  6. ISHIYAMA Y
    Editorial Comment to Impact of early postoperative creatinine increase on mid-term renal function after cystectomy.
    Int J Urol. 2022;29:724.
    PubMed    


  7. MASTROIANNI R, Simone G
    Editorial Comment to Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy.
    Int J Urol. 2022;29:684.
    PubMed    


  8. SARI MOTLAGH R, Schuettfort VM, Mori K, Katayama S, et al
    Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy.
    Int J Urol. 2022;29:676-683.
    PubMed     Abstract available


  9. TOGASHI K, Hatakeyama S, Yoneyama T, Hamaya T, et al
    Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
    Int J Urol. 2022;29:733-739.
    PubMed     Abstract available


  10. KITA Y, Ito K, Sano T, Hashimoto K, et al
    Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
    Int J Urol. 2022;29:647-655.
    PubMed     Abstract available


    June 2022
  11. TANAKA T, Shindo T, Hashimoto K, Kobayashi K, et al
    Management of hydronephrosis after radical cystectomy and urinary diversion for bladder cancer: A single tertiary center experience.
    Int J Urol. 2022 Jun 30. doi: 10.1111/iju.14970.
    PubMed     Abstract available


  12. ARAI T, Sazuka T, Sato H, Imamura Y, et al
    Efficacy of photodynamic diagnosis-assisted transurethral resection of bladder tumor for T1 bladder cancer: Novel second transurethral resection initiatives utilizing photodynamic diagnosis.
    Int J Urol. 2022 Jun 20. doi: 10.1111/iju.14962.
    PubMed    


  13. NOHARA T
    Editorial Comment to Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods.
    Int J Urol. 2022 Jun 19. doi: 10.1111/iju.14967.
    PubMed    


  14. TAOKA R, Sugimoto M
    Editorial Comment from Dr Taoka and Dr Sugimoto to Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guerin treatment.
    Int J Urol. 2022 Jun 11. doi: 10.1111/iju.14954.
    PubMed    


  15. MATSUMOTO K
    Editorial Comment from Dr Matsumoto to Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guerin treatment.
    Int J Urol. 2022 Jun 9. doi: 10.1111/iju.14955.
    PubMed    


  16. SHINDO T, Maehana T, Tanaka T, Hashimoto K, et al
    Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study.
    Int J Urol. 2022 Jun 2. doi: 10.1111/iju.14941.
    PubMed     Abstract available


  17. ZENNAMI K, Sumitomo M, Hasegawa K, Kozako M, et al
    Risk factors for postoperative ileus after robot-assisted radical cystectomy with intracorporeal urinary diversion.
    Int J Urol. 2022;29:553-558.
    PubMed     Abstract available


    May 2022
  18. LEE AY, Allen JC Jr, Teoh JY, Kang SH, et al
    Predicting perioperative outcomes of robot-assisted radical cystectomy: Data from the Asian Robot-Assisted Radical Cystectomy Consortium.
    Int J Urol. 2022 May 25. doi: 10.1111/iju.14937.
    PubMed     Abstract available


  19. WANG Z, So WZ, Loh KY, Lim YK, et al
    Predictive biomarkers of response to bacillus Calmette-Guerin immunotherapy and bacillus Calmette-Guerin failure for non-muscle invasive bladder cancer.
    Int J Urol. 2022 May 22. doi: 10.1111/iju.14921.
    PubMed     Abstract available


  20. MIYAKE M, Kikuchi E, Shinozaki K, Piao Y, et al
    Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guerin treatment.
    Int J Urol. 2022 May 21. doi: 10.1111/iju.14933.
    PubMed     Abstract available


  21. HIRATA Y, Higuchi M, Osawa T, Hinotsu S, et al
    Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods.
    Int J Urol. 2022 May 21. doi: 10.1111/iju.14936.
    PubMed     Abstract available


  22. FUJITA N, Hatakeyama S, Momota M, Narita T, et al
    Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guerin therapy.
    Int J Urol. 2022 May 16. doi: 10.1111/iju.14926.
    PubMed     Abstract available


  23. KANNO T, Kobori G, Ito K, Nakagawa H, et al
    Complications and their management following retroperitoneal lymph node dissection in conjunction with retroperitoneal laparoscopic radical nephroureterectomy.
    Int J Urol. 2022;29:455-461.
    PubMed     Abstract available


    April 2022
  24. TELLINI R, Mari A, Minervini A
    Editorial Comment from Dr Tellini et al. to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Int J Urol. 2022 Apr 5. doi: 10.1111/iju.14895.
    PubMed    


  25. HAYAKAWA N, Kikuchi E
    Editorial Comment from Dr Hayakawa and Dr Kikuchi to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Int J Urol. 2022 Apr 2. doi: 10.1111/iju.14888.
    PubMed    


  26. MIYAKE M
    Editorial Comment to Association of oncological response between the first-line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma.
    Int J Urol. 2022;29:364-365.
    PubMed    


  27. OZAKI K, Hatakeyama S, Hamaya T, Okita K, et al
    Association of oncological response between the first-line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma.
    Int J Urol. 2022;29:362-364.
    PubMed    


    March 2022
  28. NASELLI A, Pirola GM
    Editorial Comment from Dr Naselli and Dr Pirola to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Int J Urol. 2022 Mar 31. doi: 10.1111/iju.14883.
    PubMed    


  29. KOBAYASHI K, Matsuyama H, Kawai T, Ikeda A, et al
    Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Int J Urol. 2022 Mar 15. doi: 10.1111/iju.14854.
    PubMed     Abstract available


  30. URABE F, Matsuzaki J, Ito K, Takamori H, et al
    Serum microRNA as liquid biopsy biomarker for the prediction of oncological outcomes in patients with bladder cancer.
    Int J Urol. 2022 Mar 14. doi: 10.1111/iju.14858.
    PubMed     Abstract available


    February 2022
  31. IDE H
    Editorial Comment from Dr Ide to Substratification of patients with highest-risk non-muscle invasive bladder cancer helps to identify the candidates for immediate radical cystectomy: A two-center study.
    Int J Urol. 2022 Feb 25. doi: 10.1111/iju.14837.
    PubMed    


  32. KOGA F
    Editorial Comment to Predicting factor analysis of postoperative complications after robot-assisted radical cystectomy: Multicenter KORARC database study.
    Int J Urol. 2022 Feb 20. doi: 10.1111/iju.14832.
    PubMed    


  33. TAOKA R, Sugimoto M
    Editorial Comment to Substratification of patients with highest-risk non-muscle invasive bladder cancer helps to identify the candidates for immediate radical cystectomy: A two-center study.
    Int J Urol. 2022 Feb 15. doi: 10.1111/iju.14828.
    PubMed    


  34. LEOW JJ, Yong DZ, Chia PL
    Editorial Comment to Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium.
    Int J Urol. 2022 Feb 10. doi: 10.1111/iju.14818.
    PubMed    


  35. KIM H, Jeong BC, Lee S, Ku JH, et al
    Predicting factor analysis of postoperative complications after robot-assisted radical cystectomy: Multicenter KORARC database study.
    Int J Urol. 2022 Feb 8. doi: 10.1111/iju.14815.
    PubMed     Abstract available


  36. YANG T, Liang H, Pei X, Zhang N, et al
    Substratification of patients with highest-risk non-muscle invasive bladder cancer helps to identify the candidates for immediate radical cystectomy: A two-center study.
    Int J Urol. 2022 Feb 5. doi: 10.1111/iju.14808.
    PubMed     Abstract available


  37. IQBAL U, Houenstein HA, Elsayed AS, Jing Z, et al
    Ileal conduit versus neobladder: A propensity score-matched analysis of the effect on renal function.
    Int J Urol. 2022;29:158-163.
    PubMed     Abstract available


  38. LIN MY, Niu SW, Li WM, Lee HL, et al
    Incidence and survival variations of upper tract urothelial cancer in Taiwan (2001-2010).
    Int J Urol. 2022;29:121-127.
    PubMed     Abstract available


    January 2022
  39. SHINDO T
    Editorial Comment from Dr Shindo to Prognostication in Japanese patients with Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
    Int J Urol. 2022 Jan 4. doi: 10.1111/iju.14783.
    PubMed    


  40. GRAVESTOCK P, Coulthard N, Veeratterapillay R, Heer R, et al
    Response to Re: Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Jan 1. doi: 10.1111/iju.14780.
    PubMed    


  41. CHEN CS, Li JR, Yang CK, Cheng CL, et al
    Significant predictors of contralateral upper tract recurrence after radical nephroureterectomy for upper tract urothelial carcinoma.
    Int J Urol. 2022;29:69-75.
    PubMed     Abstract available


  42. KIJIMA T
    Editorial Comment to Programmed cell death-ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma.
    Int J Urol. 2022;29:91.
    PubMed    


  43. TOMIYAMA E, Fujita K, Hashimoto M, Miyamoto H, et al
    Programmed cell death-ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma.
    Int J Urol. 2022;29:89-90.
    PubMed    


    December 2021
  44. HAYAKAWA N, Kikuchi E
    Editorial Comment to Incidence and location of perioperative deep vein thrombosis in patients with bladder cancer undergoing radical cystectomy.
    Int J Urol. 2021 Dec 28. doi: 10.1111/iju.14777.
    PubMed    


  45. TAGUCHI S
    Editorial Comment from Dr Taguchi to Role of Vesical Imaging-Reporting and Data System in predicting muscle-invasive bladder cancer: A diagnostic meta-analysis.
    Int J Urol. 2021 Dec 19. doi: 10.1111/iju.14768.
    PubMed    


  46. YUAN B, Cai L, Cao Q, Wu Q, et al
    Role of Vesical Imaging-Reporting and Data System in predicting muscle-invasive bladder cancer: A diagnostic meta-analysis.
    Int J Urol. 2021 Dec 19. doi: 10.1111/iju.14748.
    PubMed     Abstract available


  47. YOSHIDA S, Fujii Y
    Editorial Comment from Dr Yoshida and Dr Fujii to Role of Vesical Imaging-Reporting and Data System in predicting muscle-invasive bladder cancer: A diagnostic meta-analysis.
    Int J Urol. 2021 Dec 19. doi: 10.1111/iju.14771.
    PubMed    


  48. GOPALAKRISHNAN D, Elsayed AS, Hussein AA, Jing Z, et al
    Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium.
    Int J Urol. 2021 Dec 19. doi: 10.1111/iju.14749.
    PubMed     Abstract available


  49. SAZUKA T
    Editorial Comment to Prognostication in Japanese patients with Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
    Int J Urol. 2021 Dec 15. doi: 10.1111/iju.14770.
    PubMed    


  50. NISHIMURA N, Miyake M, Iida K, Miyamoto T, et al
    Prognostication in Japanese patients with Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
    Int J Urol. 2021 Dec 13. doi: 10.1111/iju.14759.
    PubMed     Abstract available


  51. KIKUCHI H, Abe T, Matsumoto R, Osawa T, et al
    Outcomes of bacillus Calmette-Guerin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era.
    Int J Urol. 2021 Dec 11. doi: 10.1111/iju.14761.
    PubMed     Abstract available


  52. YAMASHITA R, Nakamura M, Okayama Y, Kawase M, et al
    Incidence and location of perioperative deep vein thrombosis in patients with bladder cancer undergoing radical cystectomy.
    Int J Urol. 2021 Dec 9. doi: 10.1111/iju.14760.
    PubMed     Abstract available


  53. GOMEZ-OSPINA JC, Garcia-Perdomo HA
    Re: Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Dec 6. doi: 10.1111/iju.14764.
    PubMed    


  54. LONATI C, Moschini M
    Editorial Comment from Dr Lonati and Dr Moschini to Stage and cancer-specific mortality differ within specific Asian ethnic groups in upper tract urothelial carcinoma: North American population-based study.
    Int J Urol. 2021;28:1252-1253.
    PubMed    


  55. SHIOTA M
    Editorial Comment from Dr Shiota to Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study.
    Int J Urol. 2021;28:1253.
    PubMed    


  56. KATO M, Kobayashi T, Matsui Y, Ito K, et al
    Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab.
    Int J Urol. 2021;28:1261-1267.
    PubMed     Abstract available


  57. COLLA RUVOLO C, Wurnschimmel C, Nocera L, Wenzel M, et al
    Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study.
    Int J Urol. 2021;28:1247-1252.
    PubMed     Abstract available


  58. SHIMIZU T, Hori S, Iemura Y, Tomioka A, et al
    Clinical significance of bladder deformity for intravesical recurrence after Bacillus Calmette-Guerin treatment.
    Int J Urol. 2021;28:1304-1305.
    PubMed    


    November 2021
  59. CHEN TJ, Chan TC, Li CF, Dilshan Sampath Dissanayaka D, et al
    High glycosyltransferase 8 domain containing two protein levels contribute to poor prognosis in urothelial carcinoma.
    Int J Urol. 2021;28:1178-1187.
    PubMed     Abstract available


    September 2021
  60. POLIKARPOV DM, Campbell DH, Zaslavsky AB, Lund ME, et al
    Glypican-1 as a target for fluorescence molecular imaging of bladder cancer.
    Int J Urol. 2021 Sep 8. doi: 10.1111/iju.14683.
    PubMed     Abstract available


  61. NASELLI A
    Editorial Comment to Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Sep 7. doi: 10.1111/iju.14687.
    PubMed    


  62. HARADA M, Tomisaki I, Minato A, Onishi R, et al
    Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
    Int J Urol. 2021;28:970-974.
    PubMed     Abstract available


  63. NARITA T, Hatakeyama S, Numakura K, Kobayashi M, et al
    Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.
    Int J Urol. 2021;28:899-905.
    PubMed     Abstract available


    August 2021
  64. GRAVESTOCK P, Coulthard N, Veeratterapillay R, Heer R, et al
    Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Aug 27. doi: 10.1111/iju.14671.
    PubMed     Abstract available


  65. SHINDO T, Hashimoto K, Tanaka T, Taguchi K, et al
    Therapeutic options to reduce intravesical recurrence in newly diagnosed Ta high-grade bladder cancer according to risk stratification: A multicenter retrospective study.
    Int J Urol. 2021 Aug 3. doi: 10.1111/iju.14657.
    PubMed     Abstract available


  66. SETOGUCHI K, Saito K
    Editorial Comment from Dr Setoguchi and Dr Saito to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:821-822.
    PubMed    


  67. SHIGA M, Nagumo Y, Chihara I, Nitta S, et al
    Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:814-819.
    PubMed     Abstract available


  68. HATAKEYAMA S, Ohyama C
    Editorial Comment from Dr Hatakeyama and Dr Ohyama to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:820.
    PubMed    


  69. SAZUKA T
    Editorial Comment from Dr Sazuka to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:820-821.
    PubMed    


    July 2021
  70. SHIN T, Mimata H
    "Early-pull-out" technique for intracorporeal ileal conduit urinary diversion after robot-assisted radical cystectomy.
    Int J Urol. 2021;28:778-779.
    PubMed    


    May 2021
  71. FAN J, Wu K, Zhang N, Yang T, et al
    Green-light laser en bloc resection versus conventional transurethral resection for initial non-muscle-invasive bladder cancer: A randomized controlled trial.
    Int J Urol. 2021 May 19. doi: 10.1111/iju.14592.
    PubMed     Abstract available


  72. MIYATA Y, Matsuo T, Sakai H
    Editorial Comment to Green-light laser en bloc resection versus conventional transurethral resection for initial non-muscle-invasive bladder cancer: A randomized controlled trial.
    Int J Urol. 2021 May 19. doi: 10.1111/iju.14607.
    PubMed    


  73. KUROBE M
    Editorial Comment from Dr Kurobe to Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data.
    Int J Urol. 2021 May 3. doi: 10.1111/iju.14594.
    PubMed    


  74. IQBAL U, Durrani MM, Elsayed AS, Hussein AA, et al
    Functional outcomes after robot-assisted radical cystectomy: A review of literature.
    Int J Urol. 2021;28:493-501.
    PubMed     Abstract available


  75. FARAJ KS, Rose KM, Navaratnam AK, Abdul-Muhsin HM, et al
    Effect of intracorporeal urinary diversion on the incidence of benign ureteroenteric stricture after cystectomy.
    Int J Urol. 2021;28:593-597.
    PubMed     Abstract available


    April 2021
  76. LONATI C, Moschini M
    Editorial Comment from Dr Lonati and Dr Moschini to Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
    Int J Urol. 2021 Apr 22. doi: 10.1111/iju.14577.
    PubMed    


  77. URABE F
    Editorial Comment from Dr Urabe to Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data.
    Int J Urol. 2021 Apr 21. doi: 10.1111/iju.14580.
    PubMed    


  78. SAITO R
    Editorial Comment from Dr Saito to Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Apr 21. doi: 10.1111/iju.14588.
    PubMed    


  79. KIJIMA T
    Editorial Comment from Dr Kijima to Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
    Int J Urol. 2021 Apr 21. doi: 10.1111/iju.14581.
    PubMed    


  80. HAYASHI Y, Fujita K, Banno E, Eich ML, et al
    Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data.
    Int J Urol. 2021 Apr 15. doi: 10.1111/iju.14574.
    PubMed    


  81. YAMASHITA S, Iguchi T, Koike H, Wakamiya T, et al
    Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
    Int J Urol. 2021 Apr 5. doi: 10.1111/iju.14569.
    PubMed     Abstract available


    March 2021
  82. TEOH JY
    Editorial Comment to Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Mar 28. doi: 10.1111/iju.14563.
    PubMed    


  83. HATANO K, Nonomura N
    Editorial Comment from Dr Hatano and Dr Nonomura to Temporal trends in the incidence of distant-stage bladder cancer among young individuals.
    Int J Urol. 2021 Mar 28. doi: 10.1111/iju.14559.
    PubMed    


  84. SETOGUCHI K, Saito K
    Editorial Comment from Dr Setoguchi and Dr Saito to Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis.
    Int J Urol. 2021 Mar 27. doi: 10.1111/iju.14561.
    PubMed    


  85. FUKUSHIMA H
    Editorial Comment from Dr Fukushima to Temporal trends in the incidence of distant-stage bladder cancer among young individuals.
    Int J Urol. 2021 Mar 26. doi: 10.1111/iju.14558.
    PubMed    


  86. TAOKA R, Tsunemori H, Matsuoka Y, Kohashiguchi K, et al
    Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Mar 19. doi: 10.1111/iju.14548.
    PubMed     Abstract available


  87. HAYAKAWA N, Kikuchi E
    Editorial Comment to Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matched-pair analysis in a multicenter cohort.
    Int J Urol. 2021 Mar 18. doi: 10.1111/iju.14557.
    PubMed    


  88. MIYAMOTO T, Miyake M, Toyoshima Y, Fujii T, et al
    Clinical outcomes after intravesical bacillus Calmette-Guerin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019.
    Int J Urol. 2021 Mar 18. doi: 10.1111/iju.14545.
    PubMed     Abstract available


  89. TULLY KH, Reese SW, Cole AP, Noldus J, et al
    Temporal trends in the incidence of distant-stage bladder cancer among young individuals.
    Int J Urol. 2021 Mar 14. doi: 10.1111/iju.14550.
    PubMed    


  90. HUANG H, Yan B, Hao H, Shang M, et al
    Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis.
    Int J Urol. 2021 Mar 13. doi: 10.1111/iju.14537.
    PubMed     Abstract available


  91. KANNO T
    Editorial Comment from Dr Kanno to Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis.
    Int J Urol. 2021 Mar 13. doi: 10.1111/iju.14551.
    PubMed    


  92. KUBOTA M, Kanno T, Inoue T, Yamasaki T, et al
    Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matched-pair analysis in a multicenter cohort.
    Int J Urol. 2021 Mar 7. doi: 10.1111/iju.14533.
    PubMed     Abstract available


    February 2021
  93. INOKUCHI J, Kuroiwa K, Nishiyama H, Kojima T, et al
    Significance of the timing of ureteral ligation on prognosis during radical nephroureterectomy for upper urinary tract urothelial cancer.
    Int J Urol. 2021;28:208-214.
    PubMed     Abstract available


    November 2020
  94. NAKAGAWA T
    Lymph node dissection for bladder cancer: Current standards and the latest evidence.
    Int J Urol. 2020 Nov 3. doi: 10.1111/iju.14398.
    PubMed     Abstract available


  95. TANAKA H, Fujii Y
    Editorial Comment to Lymph node dissection for bladder cancer: Current standards and the latest evidence.
    Int J Urol. 2020 Nov 3. doi: 10.1111/iju.14419.
    PubMed    


  96. KOJIMA T
    Editorial Comment from Dr Kojima to Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma.
    Int J Urol. 2020;27:1031.
    PubMed    


  97. YOSHIDA T, Matsuda T
    Editorial Comment from Dr Yoshida and Dr Matsuda to Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma.
    Int J Urol. 2020;27:1030-1031.
    PubMed    


    September 2020
  98. TAOKA R, Matsuoka Y, Kohashiguchi K, Miura T, et al
    Impact of second transurethral resection on recurrence in patients with high-grade Ta bladder cancer.
    Int J Urol. 2020 Sep 28. doi: 10.1111/iju.14372.
    PubMed     Abstract available


  99. KHETRAPAL P
    Editorial Comment to Benefits of robotic cystectomy compared with open cystectomy in an Enhanced Recovery After Surgery program: A propensity-matched analysis.
    Int J Urol. 2020;27:788-789.
    PubMed    


    August 2020
  100. IWASAWA T, Niwa N, Matsumoto K, Komatsuda A, et al
    Reduced recurrence of low-risk non-muscle-invasive bladder cancer is associated with low urine-specific gravity.
    Int J Urol. 2020 Aug 13. doi: 10.1111/iju.14351.
    PubMed     Abstract available


    July 2020
  101. TANAKA H
    Editorial Comment to Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision.
    Int J Urol. 2020 Jul 21. doi: 10.1111/iju.14314.
    PubMed    


    June 2020
  102. WEINER AB, Pham MN, Isaacson DS, Ko OS, et al
    Predictors of use and overall survival for patients undergoing metastasectomy for bladder cancer in a national cohort.
    Int J Urol. 2020 Jun 26. doi: 10.1111/iju.14288.
    PubMed     Abstract available


  103. MATSUMOTO H, Shiraishi K, Azuma H, Inoue K, et al
    Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision.
    Int J Urol. 2020 Jun 21. doi: 10.1111/iju.14281.
    PubMed     Abstract available


  104. SHIN T
    Editorial Comment from Dr Shin to Frailty is significantly associated with the type of urinary diversion in patients with muscle-invasive bladder cancer.
    Int J Urol. 2020 Jun 4. doi: 10.1111/iju.14282.
    PubMed    


  105. ADOMI S, Fujita K, Yoshimura K, Uemura H, et al
    Editorial Comment from Dr Adomi et al. to Frailty is significantly associated with the type of urinary diversion in patients with muscle-invasive bladder cancer.
    Int J Urol. 2020 Jun 4. doi: 10.1111/iju.14284.
    PubMed    


    May 2020
  106. OKITA K, Hatakeyama S, Momota M, Soma O, et al
    Frailty is significantly associated with the type of urinary diversion in patients with muscle-invasive bladder cancer.
    Int J Urol. 2020 May 25. doi: 10.1111/iju.14263.
    PubMed     Abstract available


    March 2020
  107. MATSUMOTO H, Shiraishi K, Azuma H, Inoue K, et al
    Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper.
    Int J Urol. 2020 Mar 14. doi: 10.1111/iju.14210.
    PubMed     Abstract available


    February 2020
  108. ABE T
    Editorial Comment from Dr Abe to Oncological outcomes and recurrence patterns after laparoscopic radical cystectomy for bladder cancer: A Japanese multicenter cohort.
    Int J Urol. 2020 Feb 5. doi: 10.1111/iju.14193.
    PubMed    


  109. TANAKA H, Fujii Y
    Editorial Comment from Dr Tanaka and Dr Fujii to Oncological outcomes and recurrence patterns after laparoscopic radical cystectomy for bladder cancer: A Japanese multicenter cohort.
    Int J Urol. 2020 Feb 5. doi: 10.1111/iju.14194.
    PubMed    


    January 2020
  110. TANAKA H, Fukushima H, Kijima T, Nakamura Y, et al
    Feasibility and outcomes of selective tetramodal bladder-preservation therapy in elderly patients with muscle-invasive bladder cancer.
    Int J Urol. 2020 Jan 19. doi: 10.1111/iju.14179.
    PubMed     Abstract available


  111. KANNO T, Inoue T, Ito K, Okumura K, et al
    Oncological outcomes and recurrence patterns after laparoscopic radical cystectomy for bladder cancer: A Japanese multicenter cohort.
    Int J Urol. 2020 Jan 16. doi: 10.1111/iju.14182.
    PubMed     Abstract available


  112. HERR H
    Does asymptomatic bacteriuria affect the response to intravesical bacillus Calmette-Guerin?
    Int J Urol. 2020;27:72-74.
    PubMed     Abstract available


    December 2019
  113. KIKUCHI E, Hayakawa N, Fukumoto K, Shigeta K, et al
    Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies.
    Int J Urol. 2019 Dec 3. doi: 10.1111/iju.14153.
    PubMed     Abstract available


    October 2019
  114. FUKUHARA H
    Editorial Comment from Dr Fukuhara to Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2019 Oct 11. doi: 10.1111/iju.14124.
    PubMed    


  115. MATSUMOTO H
    Editorial Comment from Dr Matsumoto to Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2019 Oct 6. doi: 10.1111/iju.14131.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: